Published in Biomed Res Int on October 25, 2015
Inactivated Pseudomonas aeruginosa inhibits hypoxia-induced pulmonary hypertension by preventing TGF-β1/Smad signaling. Braz J Med Biol Res (2016) 0.77
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr (2010) 13.12
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med (2014) 9.40
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Treatment of pulmonary arterial hypertension. N Engl J Med (2004) 6.88
The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med (1992) 6.40
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation (1984) 5.60
Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med (2013) 5.60
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet (2008) 5.01
Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med (2013) 4.98
Epidemiology and risk profile of heart failure. Nat Rev Cardiol (2010) 4.88
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol (2002) 4.79
Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation (2006) 4.69
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation (2002) 4.42
Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med (1999) 4.09
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med (2002) 3.91
Inhaled iloprost for severe pulmonary hypertension. N Engl J Med (2002) 3.90
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 3.86
Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science (1992) 3.80
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol (2011) 3.69
Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 3.63
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.37
Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med (2002) 3.32
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 3.23
Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci U S A (2002) 3.13
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05
Tadalafil therapy for pulmonary arterial hypertension. Circulation (2009) 2.98
The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest (2009) 2.92
Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation (1998) 2.90
Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med (1991) 2.88
Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation (2013) 2.82
Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol (2013) 2.76
Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest (2006) 2.73
Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation (2009) 2.73
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation (2006) 2.67
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation (2003) 2.57
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54
Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest (1999) 2.44
Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest (2006) 2.43
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J (2009) 2.41
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J (2006) 2.39
Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. J Am Coll Cardiol (2007) 2.29
Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2003) 2.23
Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration (2012) 2.23
Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med (2010) 2.20
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J (1997) 2.16
Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J (2003) 2.15
The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. Cardiovasc Res (2013) 2.08
Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol (2013) 2.07
Metabolic mechanisms in heart failure. Circulation (2007) 2.06
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J (2009) 2.04
Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. J Am Coll Cardiol (2008) 1.97
Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation (2011) 1.91
Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J (2009) 1.85
NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J (2006) 1.81
A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology (2010) 1.80
Pulmonary arterial hypertension: the key role of echocardiography. Chest (2005) 1.79
Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol (2013) 1.78
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2002) 1.77
Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. Chest (2006) 1.75
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2014) 1.73
Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. J Clin Invest (1998) 1.72
GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation (2012) 1.71
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med (2010) 1.69
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J (2013) 1.68
Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A (2008) 1.67
Semi-quantitative assessment of tricuspid regurgitation on contrast-enhanced multidetector CT. Clin Radiol (2004) 1.67
Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation (1996) 1.66
Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest (2006) 1.64
Successful extracorporeal membrane oxygenation support after pulmonary thromboendarterectomy. Ann Thorac Surg (2008) 1.61
Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest (1992) 1.59
Sleep disorders in systolic heart failure: a prospective study of 100 male patients. The final report. Int J Cardiol (2006) 1.59
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J (2012) 1.58
Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart (2005) 1.55
Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation (1992) 1.53
Pulmonary hypertension in interstitial lung disease. Eur Respir J (2008) 1.53
Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. Circ Res (2010) 1.52
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med (2013) 1.51
Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol (2007) 1.48
Ultrastructural appearances of pulmonary capillaries at high transmural pressures. J Appl Physiol (1985) (1991) 1.47
Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology (2013) 1.46
Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J (2006) 1.43
Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. J Mol Med (Berl) (2011) 1.43
Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation (1995) 1.41
Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest (2007) 1.40
Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum (2008) 1.40
Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol (2011) 1.36